Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Factor IX antibody and immune tolerance.

I Warrier1

  • 1State University, Children's Hospital of Michigan, Detroit, Mich., USA.

Vox Sanguinis
|October 26, 1999
PubMed
Summary

Factor IX (FIX) inhibitors are rare but challenging in haemophilia B patients. Allergy to FIX complicates immune tolerance induction (ITI), often leading to poor treatment responses and nephrotic syndrome.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Types of bleeding seen during the first 30 months of life in children with severe haemophilia A and B.

Haemophilia : the official journal of the World Federation of Hemophilia·2016
Same author

Factor IX inhibitors and anaphylaxis in haemophilia B.

Haemophilia : the official journal of the World Federation of Hemophilia·2016
Same author

Use of central venous catheters in children with haemophilia: one haemophilia treatment centre experience.

Haemophilia : the official journal of the World Federation of Hemophilia·2016
Same author

Factor IX inhibitors and anaphylaxis in hemophilia B.

Haemophilia : the official journal of the World Federation of Hemophilia·2016
Same author

Immune tolerance induction in 31 children with haemophilia A: is ITI less successful in African Americans?

Haemophilia : the official journal of the World Federation of Hemophilia·2010
Same author

Inhibitors in factor IX deficiency a report of the ISTH-SSC international FIX inhibitor registry (1997-2006).

Haemophilia : the official journal of the World Federation of Hemophilia·2009

Area of Science:

  • Hematology
  • Immunology
  • Genetics

Background:

  • Factor IX (FIX) inhibitors are significantly less prevalent than Factor VIII inhibitors.
  • FIX inhibitors present unique treatment challenges due to co-existing severe allergic reactions to FIX.
  • The development of inhibitors in haemophilia B is often associated with anaphylaxis to FIX replacement therapy.

Purpose of the Study:

  • To investigate the complexities of immune tolerance induction (ITI) in haemophilia B patients with FIX inhibitors and concurrent allergy.
  • To explore the factors contributing to poor ITI response in this patient population.
  • To understand the incidence and impact of nephrotic syndrome during ITI for haemophilia B with allergy.

Main Methods:

  • Retrospective analysis of haemophilia B patients with FIX inhibitors and allergy.
  • Review of treatment protocols and outcomes for immune tolerance induction.
  • Assessment of allergic reactions and development of nephrotic syndrome during ITI.

Main Results:

  • Patients with FIX inhibitors and allergy exhibit a high rate of treatment challenges.
  • Nephrotic syndrome is a significant complication during ITI in this cohort.
  • The overall response rate to ITI in haemophilia B patients with allergy to FIX is generally poor.

Conclusions:

  • Haemophilia B patients with FIX inhibitors and allergy require specialized management strategies.
  • Immune tolerance induction is complicated by allergic reactions and nephrotic syndrome, necessitating further research.
  • Improved therapeutic approaches are needed to enhance ITI efficacy and safety in this challenging group.

Related Experiment Videos